
Determining E&L risk from single-use components can be used to build the level of extractable profiling and PERLs.
Somasundaram Gopalakrishnan, is senior consultant, Global Biopharm Center of Excellence, Merck Pte. Ltd.

Determining E&L risk from single-use components can be used to build the level of extractable profiling and PERLs.

The evolution of therapeutic modalities drives the adoption of single-use technologies.

Published: March 15th 2024 | Updated: